Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Tucson, ArizonaAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05961111RecruitingEarly Phase 1
Oncolytic virus injection for advanced solid tumors
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
Linyi, ShandongAges 18–75 - NCT06010342RecruitingPhase 2
TL118 for solid tumors with NTRK fusion
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
Glendale, CaliforniaAges 18 years+ - NCT06251310RecruitingPhase 1
Testing SW-682 in Advanced Solid Tumors
This trial tests a new drug (SW-682) for people with advanced solid tumors that have stopped responding to standard treatments. It focuses on cancers with specific gene changes (NF2 or Hippo pathway) and aims to see if the drug can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT06521554RecruitingPhase 1
Study of NVL-330 for HER2-altered advanced lung cancer
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Irvine, CaliforniaAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
Aurora, ColoradoAges 6 months–17 years - NCT06723236RecruitingPhase 1
Study of MGC028 for Advanced Solid Tumors
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06730750RecruitingPhase 1/Phase 2
Study of BMS-986490 with or without bevacizumab for advanced solid tumors
This study tests a new drug called BMS-986490, either alone or with bevacizumab, for people with advanced solid tumors like colorectal, lung, or stomach cancer that has not responded to standard treatments. The goal is to see if the drug can shrink tumors and help people live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT06907043RecruitingPhase 1/Phase 2
Study of PARP1 inhibitor EIK1004 for advanced solid tumors
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
Denver, ColoradoAges 18–89 - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT07035249RecruitingPhase 1/Phase 2
DCSZ11 plus standard therapy for advanced solid tumors
This trial tests a new drug called DCSZ11 combined with usual chemotherapy and immunotherapy for people with advanced or metastatic solid tumors. It aims to see if adding DCSZ11 works better than standard treatments alone.
Chengdu, SichuanAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,461 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.